Skip to main content
Premium Trial:

Request an Annual Quote

Nuvelo Nets $26M From Stock Offering

NEW YORK, Oct. 7 (GenomeWeb News) - Nuvelo, the company created when Hyseq merged with Variagenics in November 2002, announced today that it has raised $26 million as the net proceeds after sales of 11.5 million new shares of its stock.

 

The company, based in Sunnyvale, Calif. said it plans to use the proceeds of the previously-announced financing for clinical trials of its lead drug candidate. 

 

In August, Nuvelo said it would sell its pharmacogenomics assets from Variagenics and its microarray assets from Hyseq in order to focus on drug development. (See the article in SNPtech Reporter 08-07-03).

 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.